CBD Gel for Bruxism: Why Similar Results Do Not Prove Equal Strengths

A small controlled trial reported improvements with both 5% and 10% CBD gels, without a significant difference between strengths. That is not a formal demonstration that the two strengths are therapeutically equivalent.

The intervention and outcomes

Sixty participants with bruxism-associated muscular pain were assigned equally to placebo, 5% CBD gel or 10% CBD gel. The gels were applied intraorally over a 30-day period. Outcomes included sleep-quality and migraine-disability questionnaires, with muscle-activity assessments also reported.

This was a specific localized formulation in a selected clinical population. Its results should not be generalized to all CBD creams, ordinary swallowed CBD or every cause of migraine and poor sleep.

A positive comparison and a null comparison

The CBD groups showed significant questionnaire improvements compared with control. The comparison between CBD strengths was not significant. Those statements answer different questions: whether each treatment differed from placebo, and whether the study detected a difference between the active treatments.

Equivalence requires a justified margin and an analysis capable of excluding clinically important differences. Failure to detect a difference is insufficient, especially in a small sample.

Sample-size and mechanism limitations

The methods acknowledge a recalculation indicating approximately 26 participants per group would have been needed under the stated planning assumptions, compared with 20 actually studied. A post hoc power calculation does not erase uncertainty in the active-strength comparison.

Associations between reduced muscle activity and improved questionnaires do not establish the entire mechanism. The trial also did not establish long-term benefit, a systemic CBD concentration or a driving-impairment outcome. Its findings support further investigation of the particular intervention, with the strength of each inference matched to the design.

Related analysis

See our analysis of why a cannabinoid formulation is part of the exposure.

Primary research

Karolina Walczyńska-Dragon and colleagues. Expanding the Therapeutic Profile of Topical Cannabidiol in Temporomandibular Disorders: Effects on Sleep Quality and Migraine Disability in Patients with Bruxism-Associated Muscle Pain. Pharmaceuticals, 2025. DOI: 10.3390/ph18071064.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

THC/CBD Rat Brain Imaging: Why Dose and Anesthesia Limit ‘Protection’ Claims

A rat imaging study found distinct THC, CBD and combination patterns in connectivity and blood flow. The mixture moderated some THC-associated findings, but the experiment does not establish a human protective ratio or a validated impairment test. The exposures were not identical across arms Adult male rats received injected THC,…

Spread the love

Read Article: THC/CBD Rat Brain Imaging: Why Dose and Anesthesia Limit ‘Protection’ Claims

Matching Plasma THC Peaks Did Not Match Brain Exposure Across Routes in Rats

Comparable peak circulating THC did not produce identical brain and metabolite profiles after injected versus inhaled THC in rats. Matching one parent-drug concentration therefore did not make the two routes biologically interchangeable. A direct route comparison Adult male and female Sprague–Dawley rats received intraperitoneal THC or a 15-minute inhalation exposure….

Spread the love

Read Article: Matching Plasma THC Peaks Did Not Match Brain Exposure Across Routes in Rats

A Urine Paper Titled ‘THC Quantification’ Actually Targeted THC-COOH

The analyte in a laboratory method matters more than shorthand in its title. A paper titled as urinary THC quantification describes a confirmatory method for THC-COOH, the carboxy metabolite. That is not a measurement of active parent THC or contemporaneous impairment. What the method measured The investigators developed solid-phase extraction…

Spread the love

Read Article: A Urine Paper Titled ‘THC Quantification’ Actually Targeted THC-COOH

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us